Your search returned 2 results.

Results
	1.	Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. [electronic resource] by Meneses-Lorente, Georgina Friess, Thomas Kolm, Irene Hölzlwimmer, Gabriele Bader, Sabine Meille, Christophe Thomas, Marlene Bossenmaier, Birgit Producer: 20150526 In: Cancer chemotherapy and pharmacology vol. 75 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. [electronic resource] by Mirschberger, Christian Schiller, Christian B Schräml, Michael Dimoudis, Nikolaos Friess, Thomas Gerdes, Christian A Reiff, Ulrike Lifke, Valeria Hoelzlwimmer, Gabriele Kolm, Irene Hopfner, Karl-Peter Niederfellner, Gerhard Bossenmaier, Birgit Producer: 20140220 In: Cancer research vol. 73 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search